Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation

Current Opinion in Pharmacology

Volumn 4, Issue 4, 2004, Pages 378-385

  Dinarello, Charles A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CASPASE INHIBITOR; CYTOKINE RECEPTOR; ETANERCEPT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT ONSET STILL DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; GRANULOMATOSIS; HUMAN; INFLAMMATORY DISEASE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TUBERCULOSIS;

EID: 3342980733     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2004.03.010     Document Type: Review

References (56)

1. Granowitz E.V. Porat R. Mier J.W. Orencole S.F. Callahan M.V. Cannon J.G. Lynch E.A. Ye K. Poutsiaka D.D. Vannier E. et al. Hematological and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans Blood 82 1993 2985-2990
2. Granowitz E.V. Porat R. Mier J.W. Pribble J.P. Stiles D.M. Bloedow D.C. Catalano M.A. Wolff S.M. Dinarello C.A. Pharmacokinetics, saftey, and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans Cytokine 4 1992 353-360
3. Smith J.W. Longo D. Alford W.G. Janik J.E. Sharfman W.H. Gause B.L. Curti B.D. Creekmore S.P. Holmlund J.T. Fenton R.G. et al.The effects of treatment with interleukin-1α on platelet recovery after high-dose carboplatin N Engl J Med 328 1993 756-761
4. Smith J.W. Urba W.J. Curti B.D. Elwood L.J. Steis R.G. Janik J.E. Sharfman W.H.Miller L.L. Fenton R.G. Conlon K.C. et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies J Clin Oncol 10 1992 1141-1152
5. Gottlieb A.B. Masud S. Ramamurthi R. Abdulghani A. Romano P. Chaudhari U. Dooley L.T. Fasanmade A.A. Wagner C.L. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris J Am Acad Dermatol 48 2003 68-75
6. Eastgate J.A. Symons J.A. Wood N.C. Grinlinton F.M. di Giovine F.S. Duff G.W. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis Lancet 2 1988 706-709
7. Ulfgren A.K. Grondal L. Lindblad S. Khademi M. Johnell O. Klareskog L. Andersson U. Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment Ann Rheum Dis 59 2000 439-447
8. Arend W.P. Malyak M. Smith M.F. Whisenand T.D. Slack J.L.Sims J.E. Giri J.G. Dower S.K. Binding of IL-1α, IL-1β, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids J Immunol 153 1994 4766-4774
9. Auron P.E. Webb A.C. Rosenwasser L.J. Mucci S.F.Rich A. Wolff S.M. Dinarello C.A. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA Proc Natl Acad Sci USA 81 1984 7907-7911
10. Dinarello C.A. Cannon J.G. Mier J.W. Bernheim H.A. LoPreste G. Lynn D.L. Love R.N. Webb A.C. Auron P.E. Reuben R.C. et al. Multiple biological activities of human recombinant interleukin 1 J Clin Invest 77 1986 1734-1739
11. Dinarello C.A. Cannon J.G. Wolff S.M. Bernheim H.A. Beutler B.Cerami A. Figari I.S. Palladino Jr. M.A. J Exp Med 163 1986 1433-1450
12. Brennan F.M. Chantry D. Jackson A. Maini R. Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin- 1 production in rheumatoid arthritis Lancet 2 1989 244-247
13. Ulfgren A.K. Andersson U. Engstrom M. Klareskog L. Maini R.N. Taylor P.C. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis Arthritis Rheum 43 2000 2391-2396
14. Probert L. Plows D. Kontogeorgos G. Kollias G. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice Eur J Immunol 25 1995 1794-1797
15. Fong Y. Tracey K.J. Moldawer L.L. Hesse D.G. Manogue K.B. Kenney J.S. Lee A.T. Kuo G.C. Allison A.C. Lowry S.F. et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia J Exp Med 170 1989 1627-1633
16. Keane J. Gershon S. Wise R.P. Mirabile-Levens E. Kasznica J. Schwieterman W.D. Siegel J.N. Braun M.M. Tuberculosis associated with infliximab, a tumor necrosis factor-α-neutralizing agent N Engl J Med 345 2001 1098-1104
17. Siegel J. FDA briefing document on safety and efficacy update on approved TNF-blocking agents. 2003 URL: http://www.FDA.gov/ohrms/dockets/ac/03]
18. Scallon B. Cai A. Solowski N. Rosenberg A. Song X.Y. Shealy D. Wagner C. Binding and functional comparisons of two types of tumor necrosis factor antagonists J Pharmacol Exp Ther 301 2002 418-426
19. Frishman J.I. Edwards C.K. Sonnenberg M.G. Kohno T. Cohen A.M. Dinarello C.A. Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors J Infect Dis 182 2000 1722-1730
20. Tartaglia L.A. Pennica D. Goeddel D.V. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor J Biol Chem 268 1993 18542-18548
21. Yamada H. Mizumo S. Horai R. Iwakura Y. Sugawara I. Protective role of interleukin-1 in mycobacterial infection in IL-1 alpha/beta double-knockout mice Lab Invest 80 2000 759-767
22. Flynn J.L. Goldstein M.M. Chan J. Triebold K.J. Pfeffer K. Lowenstein C.J. Schreiber R. Mak T.W. Bloom B.R. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice Immunity 2 1995 561-572
23. Mohan V.P. Scanga C.A.Yu K. Scott H.M. Tanaka K.E.Tsang E. Tsai M.M. Flynn J.L. Chan J. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology Infect Immun 69 2001 1847-1855
24. Zou J. Rudwaleit M. Brandt J. Thiel A. Braun J. Sieper J. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab Arthritis Rheum 48 2003 780-790
25. Fleischmann R.M. Schechtman J. Bennett R. Handel M.L. Burmester G.R. Tesser J. Modafferi D. Poulakos J. Sun G. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial Arthritis Rheum 48 2003 927-934
26. Wallis R.S. Broder M.S. Wong J.Y. Hanson M.E. Beenhouwer D.O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists Clin Infect Dis 38 2004 1261-1265
27. Ottenhoff T.H. Verreck F.A. Lichtenauer-Kaligis E.G. Hoeve M.A. Sanal O. van Dissel J.T. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae Nat Genet 32 2002 97-105
28. Netea M.G. Radstaske T. Joosten L.A. Van der Meer J.W. Barrera P. Kullberg B.J. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy Arthr Rheumat 48 2003 1853-1857
29. Zou J. Rudwaleit M. Brandt J. Thiel A. Braun J. Sieper J. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept Ann Rheum Dis 62 2003 561-564
30. Wallis R.S. Kyambadde P. Johnson J.L. Horter L. Kittle R. Pohle M. Ducar C. Millard M. Mayanja-Kizza H. Whalen C. et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis Aids 18 2004 257-264
31. Fantuzzi G. Puren A.J. Harding M.W. Livingston D.J. Dinarello C.A. IL-18 regulation of IFN-γ production and cell proliferation as revealed in interleukin-1β converting enzyme-deficient mice Blood 91 1998 2118-2125
32. Economides A.N. Carpenter L.R. Rudge J.S. Wong V. Koehler-Stec E.M. Hartnett C. Pyles E.A. Xu X. Daly T.J. Young M.R. et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action Nat Med 9 2003 47-52
33. Wherry J.C. Schreiber R.D. Unanue E.R. Regulation of gamma interferon production by natural killer cells in scid mice: roles of tumor necrosis factor and bacterial stimuli Infect Immun 59 1991 1709-1715
34. Rudinskaya A. Trock D.H. Successful treatment of a patient with refractory adult-onset Still's disease with anakinra J Clin Rheumatol 9 2003 330-332
35. Hawkins P.N. Lachmann H.J. Aganna E. McDermott M.F. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra Arthr Rheumat 50 2004 607-612
36. Hoffman H.M. Mueller J.L. Broide D.H. Wanderer A.A. Kolodner R.D. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome Nat Genet 29 2001 301-305
37. Hoffman H.M. Wanderer A.A. Broide D.H. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever J Allergy Clin Immunol 108 2001 615-620
38. Hoffman H.M. Gregory S.G. Mueller J.L. Tresierras M. Broide D.H. Wanderer A.A. Kolodner R.D. Fine structure mapping of CIAS1: identification of an ancestral haplotype and a common FCAS mutation, L353P Hum Genet 112 2003 209-216
39. Hoffman H.M. Wright F.A. Broide D.H. Wanderer A.A. Kolodner R.D. Identification of a locus on chromosome 1q44 for familial cold urticaria Am J Hum Genet 66 2000 1693-1698
40. Kokkinos A. Iliopoulos A. Greka P. Efthymiou A. Katsilambros N. Sfikakis P.P. Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients Clin Rheumatol 23 2004 45-49
41. Charles P. Elliott M.J. Davis D. Potter A. Kalden J.R. Antoni C. Breedveld F.C. Smolen J.S. Eberl G. deWoody K. et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis J Immunol 163 1999 1521-1528
42. Tschopp J. Martinon F. Burns K. NALPs: a novel protein family involved in inflammation Nat Rev Mol Cell Biol 4 2003 95-104
43. Lovell D.J. Bowyer S.L. Treatment of neonatal onset multisystem inflammatory disease (NOMID) with IL-1Ra (anakinra) Arthr Rheumat 48 Suppl 2003 S517
44. Agostini L. Martinon F. Burns K. McDermott M.F. Hawkins P.N. Tschopp J. NALP3 forms an IL-1β processing inflammasome with increased activity in Muckle-Wells auto-inflammatory disorder Immunity 20 2004 319-325
45. Crown J. Jakubowski A. Gabrilove J. Interleukin-1: biological effects in human hematopoiesis Leuk Lymphoma 9 1993 433-440
46. Crown J. Jakubowski A. Kemeny N. Gordon M. Gasparetto C. Wong G. Toner G. Meisenberg B. Botet J. Applewhite J. et al. A phase I trial of recombinant human interleukin-1β alone and in combination with myelosuppressive doses of 5-fluoruracil in patients with gastrointestinal cancer Blood 78 1991 1420-1427
47. Dinarello C.A. Biological basis for interleukin-1 in disease Blood 87 1996 2095-2147
48. Schindler R. Mancilla J. Endres S. Ghorbani R. Clark S.C. Dinarello C.A. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF Blood 75 1990 40-47
49. Solle M. Labasi J. Perregaux D.G. Stam E. Petrushova N. Koller B.H. Griffiths R.J. Gabel C.A. Altered cytokine production in mice lacking P2X(7) receptors J Biol Chem 276 2001 125-132
50. Andrei C. Dazzi C. Lotti L. Torrisi M.R. Chimini G. Rubartelli A. The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles Mol Biol Cell 10 1999 1463-1475
51. Goupille P. Giraubeau B. Conrozier T. Marliere J. Kiefer P. Chevalier X. Safety and efficacy of intra-articular injection of IL-1ra (IL-1 receptor antagonist) in patients with painful osteroarthritis of the knee: a multicenter, double blnd study Arthr Rheumat 48 Suppl 2003 S696
52. Buch M.H. Conaghan P.G. Quinn M.A. Bingham S.J. Veale D. Emery P: True infliximab resistance in rheumatoid arthritis; a role for lymphotoxin-alpha? Ann Rheum Dis 2004, in press.
53. Rooney T. Madigan A. Greenan L. Gogarty M. FitzGerald O. Veale D.J. Dayer J.M. Bresnihan B. Combination therapy with anakinra and pegylated soluble tumor necrosis factor receptor type I (pegsunercept) in rheumatoid arthritis Arthr Rheumat 48 Suppl 2003 S704
54. Buch M.H. Bingham S.J. Seto Y. McGonagle D. Bejarano V. White J. Emery P. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade Arthritis Rheum 50 2004 725-728
55. Bresnihan B. Alvaro-Gracia J.M. Cobby M. Doherty M. Domljan Z. Emery P. Nuki G. Pavelka K. Rau R. Rozman B. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist Arthritis Rheum 41 1998 2196-2204
56. Hoffman H.M. Rosengren S. Boyle D.L. Cho J.Y. Nayar J. Mueller J.L. Anderson J.P. Wanderer A.A. Firestein G.S. Interleukin-1 receptor antagonist prevents cold-associated acute inflammation in familail cold autoinflammatory syndrome. Lancet 2004, in press.